| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/17/2005 | EP1154795B1 Means for treating and diagnosing restless legs syndrome |
| 08/17/2005 | EP1154776B1 Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism |
| 08/17/2005 | EP1150682B1 UBIQUINONE Qn FOR THE TREATMENT OF MIGRAINE PAINS |
| 08/17/2005 | EP1144385B1 Benzoheterocycles and their use as mek inhibitors |
| 08/17/2005 | EP1140103B1 Ponazuril for treating neurologic and abortigenic diseases caused by coccidia. |
| 08/17/2005 | EP1121105B1 Propofol-based anesthetic and method of making same |
| 08/17/2005 | EP1120100B1 Antibacterial agents and process for producing the same |
| 08/17/2005 | EP1109908B1 Methods for determining compounds for modulating the body weight |
| 08/17/2005 | EP1100878B8 Process for producing genetically modified cd34-negative adherently growing haematopoietic stem cells |
| 08/17/2005 | EP1087943B1 Therapeutic biaryl derivatives |
| 08/17/2005 | EP1087775B1 Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
| 08/17/2005 | EP1051500B1 Diagnosis and treatment of aur1 and/or aur2 related disorders |
| 08/17/2005 | EP1039891B1 Treatment of scar tissue using lipoic acid |
| 08/17/2005 | EP1023445B1 Cadherin derived growth factor and the application thereof |
| 08/17/2005 | EP1023067B9 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 08/17/2005 | EP1011710B1 Methods and compositions for optimization of oxygen transport by cell-free systems |
| 08/17/2005 | EP1003478B1 Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols |
| 08/17/2005 | EP0991638B1 NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS |
| 08/17/2005 | EP0990650B1 Tricyclic pyrrole or pyrazole derivatives |
| 08/17/2005 | EP0989982B1 Barbituric acid derivatives with antimetastatic and antitumor activity |
| 08/17/2005 | EP0984983B1 Modulators of intracellular inflammation, cell death and cell survival pathways containing a card and a kinase domain |
| 08/17/2005 | EP0938305B1 Method of alleviating pain by means of combining tramadol with an nmda antagonist |
| 08/17/2005 | EP0894085B1 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
| 08/17/2005 | EP0837880B1 Enamel matrix related polypeptide |
| 08/17/2005 | CN1656237A Antiviral inhibition of capsid proteins |
| 08/17/2005 | CN1656222A Antisense iap nucleobase oligomers and uses thereof |
| 08/17/2005 | CN1656212A Novel antiretroviral sulpholipids extracted from spirulinae, method for obtaining same, compositions containing same and use thereof as inhibitors of the HIV virus reverse transcriptase |
| 08/17/2005 | CN1656178A Oil-soluble pigment compositions |
| 08/17/2005 | CN1656125A Extraction of unmilled psyllium |
| 08/17/2005 | CN1656114A Novel pancortin-pablo protein interactions and methods of use thereof |
| 08/17/2005 | CN1656113A Sialic combined immunoglobulin like agglutinin inhibitors |
| 08/17/2005 | CN1656109A Non nucleoside reverse transcriptase inhibitors |
| 08/17/2005 | CN1656101A Esters in position 20 of camptothecins |
| 08/17/2005 | CN1656100A Camptothecins with a modified lactone ring |
| 08/17/2005 | CN1656099A 3-heteroaryl-3, 5-dihydro-4-oxo-4h-pyridazino[4, 5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments |
| 08/17/2005 | CN1656097A Xanthine phosphodiesterase V inhibitor polymorphs |
| 08/17/2005 | CN1656096A Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders |
| 08/17/2005 | CN1656094A 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders |
| 08/17/2005 | CN1656093A 3-substituted quinuclidines and their use |
| 08/17/2005 | CN1656092A Robertson Graeme Michael et al. |
| 08/17/2005 | CN1656090A Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
| 08/17/2005 | CN1656089A Phenyl-thiophene type vitamin D receptor modulators |
| 08/17/2005 | CN1656088A Substituted chroman derivatives having cytochrome P450RAI inhibitory activity |
| 08/17/2005 | CN1656087A Therapeutic ion channel blocking agents and methods of use thereof |
| 08/17/2005 | CN1656084A Hydroxymorpholinone derivative and medicinal use thereof |
| 08/17/2005 | CN1656083A Novel heterocyclic compounds having antibacterial activity; process for their preparation and pharmaceutical compositions containing them |
| 08/17/2005 | CN1656082A Protein kinase inhibitors |
| 08/17/2005 | CN1656081A 4-anilino quinazoline derivatives as antiproliferative agents |
| 08/17/2005 | CN1656079A Pyrazole compounds and pharmaceutical compositions comprising the compound |
| 08/17/2005 | CN1656078A Aminoindazole derivatives as protein kinase inhibitor |
| 08/17/2005 | CN1656077A Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors |
| 08/17/2005 | CN1656075A Quinoline derivatives and their use as 5-HT6 ligands |
| 08/17/2005 | CN1656073A Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| 08/17/2005 | CN1656072A Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors |
| 08/17/2005 | CN1656071A New piperidine derivative |
| 08/17/2005 | CN1656070A Melanocortin receptor ligands |
| 08/17/2005 | CN1656069A 1-(aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/17/2005 | CN1656067A New salts |
| 08/17/2005 | CN1656066A Pharmaceutical combination |
| 08/17/2005 | CN1656061A Organic compounds |
| 08/17/2005 | CN1656058A Amide derivatives as inhibitors of the enzymatic activity of renin |
| 08/17/2005 | CN1656057A N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors |
| 08/17/2005 | CN1655848A Use of new etonogestrel esters |
| 08/17/2005 | CN1655847A Self-administered contraceptive injection of oily solution |
| 08/17/2005 | CN1655846A Combination of a PDE inhibitor and a leukotriene receptor antagonist |
| 08/17/2005 | CN1655834A Method and device for controlling drug pharmacokinetics |
| 08/17/2005 | CN1655833A Medical devices containing rapamycin analogs |
| 08/17/2005 | CN1655826A Non-viral gene delivery system |
| 08/17/2005 | CN1655825A Non-viral gene delivery system |
| 08/17/2005 | CN1655824A Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same |
| 08/17/2005 | CN1655823A Topically applicable pharmaceutical preparation |
| 08/17/2005 | CN1655822A Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
| 08/17/2005 | CN1655821A Combination comprising a CDK inhibitor and doxorubicin |
| 08/17/2005 | CN1655820A Pharmaceutical combination of PDE5 inhibitors with ace inhibitors |
| 08/17/2005 | CN1655819A Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| 08/17/2005 | CN1655818A Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
| 08/17/2005 | CN1655817A Oxygenating agents for enhancing host responses to microbial infections |
| 08/17/2005 | CN1655816A Drugs for treating vascular diseases |
| 08/17/2005 | CN1655815A Process for the preparation and activation of substances and a means of producing same |
| 08/17/2005 | CN1655814A Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 08/17/2005 | CN1655813A Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 08/17/2005 | CN1655811A 组合物及其治疗用途 The composition and therapeutic use |
| 08/17/2005 | CN1655809A Compositions and methods for treating and preventing necrosis |
| 08/17/2005 | CN1655807A Composition against periodontal bacteria and foods, drinks and mouth washers against periodontal bacteria containing the composition |
| 08/17/2005 | CN1655806A Treatment of diseases involving defective gap junctional communication |
| 08/17/2005 | CN1655804A Method and composition for treating cardiovascular diseases by employing neuroregulation protein |
| 08/17/2005 | CN1655802A Bioadhesive directed somatic cell therapy |
| 08/17/2005 | CN1655801A Method for the protection of endothelial and epithclial cells during chemotherapy |
| 08/17/2005 | CN1655800A Chloasma amelioration composition and dullness amelioration composition |
| 08/17/2005 | CN1655799A Antiinflammatory agent, agent for preventing/ameliorating allergic diseases and functional food |
| 08/17/2005 | CN1655797A Use of carbon-2-modified-19-nor-vitamin D analogs to induce the formation of new bone |
| 08/17/2005 | CN1655796A Treatment of post-menopausal complaints in breast cancer patients which comprises tibolone and a SERM |
| 08/17/2005 | CN1655795A Progestagenic dosage units |
| 08/17/2005 | CN1655794A Norethindrone sustained release formulations and methods associated therewith |
| 08/17/2005 | CN1655793A A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| 08/17/2005 | CN1655792A Combination product of a 1, 4-benzothiepine 1, 1-dioxide compound with at least one other active ingredient and the use of the product |
| 08/17/2005 | CN1655791A Peritoneal dialysis solution with taurolidine |
| 08/17/2005 | CN1655790A Medicinal composition |
| 08/17/2005 | CN1655789A New pharmaceutical compositions containing flibanserin polymorph A |
| 08/17/2005 | CN1655788A 1H-imidazo[4, 5-c]quinoline derivatives in the treatment of protein kinase dependent diseases |